Don’t miss the latest developments in business and finance.

Marksans Pharma receives UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution

Image
Capital Market
Last Updated : Jan 23 2023 | 1:50 PM IST
Marksans Pharma announced that UK MHRA has granted Market Authorisation to the Company's wholly owned subsidiary Relonchem Limited for Fluoxetine 20mg/5ml Oral Solution.

Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders.

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) located at Gifford House, Slaidburn Crescent, Southport, UK.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Jan 23 2023 | 1:41 PM IST

Next Story